CDH1 and prostate adenocarcinoma: Statistical analyses of our results confirm previously reported studies on the loss of E-cadherin expression in prostatic adenocarcinoma and the negative correlation between E-cadherin immunostaining and GSC (Table 3) [11,15,16,17,18,19].